Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.

NO_LONGER_AVAILABLE

Conditions studied: Parkinson Disease

In brief

This Expanded Access IND is to evaluate the safety of multiple intravenous administrations of HB-adMSCs for treating Parkinson's disease in 10 patients between 76 and 95 y/o who do not qualify for other investigations.The dose to use for this expanded access is 200 million HB-adMSCs, administered through intravenous infusion only, with a treatment duration of 18 weeks. The program includes an up to 28 days screening period, an 18-week Treatment Period, and a 6-week Safety Follow-up Period.

Key facts

Study ID

NCT04772378

Run by

Hope Biosciences Research Foundation

Last updated by the study team

2025-09-29

Who can join

Age: 76 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A participant will be eligible for inclusion in this expanded access program only if all the following criteria apply:
• Patients aged 76-95 years old (male and female).
• Patients must have had a Parkinson's disease diagnosis for a minimum of six months before 1st infusion.
• Patients must have previously banked their mesenchymal stem cells with Hope Biosciences.
• Patients should be able to read, understand, and provide voluntarily written consent.
• Patients able and willing to comply with the requirements of this expanded access program.

You may not qualify if…

• A participant will not be eligible for inclusion in this expanded access program if any of the following criteria apply:
• Patients with advanced Parkinson's disease. Advanced PD is defined as a significant disability, wheelchair-bound or bedridden.
• Any malignancy or clinical evidence that supports the presence of a malignant process in a patient is being investigated. Malignancy is defined as any form of cancer that had occurred in the previous five years before the first infusion and may require surgery, chemotherapy, or radiation.
• Patients with medical history of uncontrolled high blood pressure defined as a deficient standard of care treatment and/or blood pressure > 140/90 mm/Hg during screening visit.
• Patients with the following concomitant or past medical history:
• Heart Failure - New York Heart Association (NYHA) Class III/IV.
• Heart Attack (in the past six months before 1st infusion).
• Stroke (in the past six months before 1st infusion).
• Hepatitis B or C.
• Human immunodeficiency virus (HIV) infection.
• Any of the following abnormal lab findings during screening will disqualify a patient from this expanded access program:
• Hemoglobin (Hgb) <10 G/DL or >18 G/DL
• Hematocrit (HCT) <30% or >54 %
• Platelet count < 80 K/UL and or > 450 K/UL.
• White blood cell count WBC < 3.0 K/UL and > 12.0 K/UL.
• Alanine aminotransferase (ALT) of > 75 IU/L
• Aspartate aminotransferase (AST) of > 75 IU/L
• eGFR < 59 mL/min/1.73
• Pre-prandial glucose > 130 MG/DL
• Post-prandial glucose > 200 MG/DL
• Patients who have received any stem cell treatment in the past six months before 1st infusion other than stem cells produced by Hope Biosciences.
• Patients who are unlikely to complete the visits or adhere to the procedures.
• The patient has previously been diagnosed with a psychiatric disorder, which is currently uncontrolled.
• Patients with a history of addiction or dependency or currently abusing or using substances.
• Patients with any form of kidney dialysis will be excluded from participation in the investigation.

Where it is running

• Hope Biosciences Stem Cell Research Foundation — Sugar Land, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.